Associated Genetic Biomarkers
Fibroblast growth factor receptor substrate 2 (FRS2) is a gene that encodes an adapter protein that links NGF and FGR receptors to downstream signaling pathways. The protein is also important for the activation of MAP kinases and PIK3R1. Missense, nonsense, and silent mutations are observed in cancers such as endometrial cancer, intestinal cancer, and skin cancer.
FRS2 is altered in 2.66% of all cancers with breast carcinoma, non-small cell lung carcinoma, colorectal adenocarcinoma, melanoma, and ovarian neoplasm having the greatest prevalence of alterations .
The most common alterations in FRS2 are FRS2 Amplification (0.08%), FRS2 Mutation (0.04%), FRS2 E360K (0.00%), FRS2 E39* (0.00%), and FRS2 E408K (0.00%) .
FRS2 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains FRS2 status as an inclusion criterion, 1 is phase 1 (1 open).
Trials with FRS2 status in the inclusion eligibility criteria most commonly target hepatocellular carcinoma and malignant solid tumor .
The most frequent alterations to serve as inclusion eligibility criteria are FRS2 Amplification, FRS2 Mutation, and FRS2 Overexpression .
Significance of FRS2 in Diseases
Malignant Solid Tumor +
Hepatocellular Carcinoma +
FRS2 is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRS2 status and hepatocellular carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 4. This dataset does not represent the totality of the genetic landscape; see paper for more information.